15
Dec
2022
Amgen Buys Horizon, Mirati’s KRAS Drug OK, & Nimbus’s Tyk2 Windfall
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Dec
2022
Prescribing Cancer Drugs Off-Label is Tricky. Transparency and Standards Are Needed
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.